- Home
- BANX vs XFOR Comparison
BANX vs XFOR Comparison
Compare BANX & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BANX
- XFOR
- Stock Information
- Founded
- BANX 2013
- XFOR 2014
- Country
- BANX United States
- XFOR United States
- Employees
- BANX N/A
- XFOR N/A
- Industry
- BANX Trusts Except Educational Religious and Charitable
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BANX Finance
- XFOR Health Care
- Exchange
- BANX Nasdaq
- XFOR Nasdaq
- Market Cap
- BANX 146.9M
- XFOR 118.4M
- IPO Year
- BANX N/A
- XFOR N/A
- Fundamental
- Price
- BANX $21.02
- XFOR $1.48
- Analyst Decision
- BANX
- XFOR Strong Buy
- Analyst Count
- BANX 0
- XFOR 3
- Target Price
- BANX N/A
- XFOR $72.33
- AVG Volume (30 Days)
- BANX 23.4K
- XFOR 436.5K
- Earning Date
- BANX 06-17-2025
- XFOR 08-07-2025
- Dividend Yield
- BANX 9.66%
- XFOR N/A
- EPS Growth
- BANX N/A
- XFOR N/A
- EPS
- BANX 2.35
- XFOR 2.16
- Revenue
- BANX $29,467,794.00
- XFOR $31,364,000.00
- Revenue This Year
- BANX N/A
- XFOR $1,106.53
- Revenue Next Year
- BANX N/A
- XFOR N/A
- P/E Ratio
- BANX $8.88
- XFOR $0.66
- Revenue Growth
- BANX 2.73
- XFOR N/A
- 52 Week Low
- BANX $17.99
- XFOR $1.42
- 52 Week High
- BANX $21.67
- XFOR $26.96
- Technical
- Relative Strength Index (RSI)
- BANX 57.31
- XFOR 25.85
- Support Level
- BANX $20.60
- XFOR $1.81
- Resistance Level
- BANX $21.24
- XFOR $2.12
- Average True Range (ATR)
- BANX 0.34
- XFOR 0.21
- MACD
- BANX 0.01
- XFOR -0.01
- Stochastic Oscillator
- BANX 77.32
- XFOR 1.88
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. Its objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.